Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Research Watch

BCL6-Driven Lymphoma Is Dependent on LSD1 Corepression

DOI: 10.1158/2159-8290.CD-RW2018-216 Published February 2019
  • Article
  • Info & Metrics
  • PDF
Loading
  • Major finding: BCL6 recruits LSD1 to enhancers to silence genes and promote germinal center–derived lymphomagenesis.

  • Concept: Blocking LSD1 enzymatic activity is insufficient to suppress BCL6-driven lymphoma cell proliferation.

  • Impact: Destabilization of LSD1 interactions may be a potential therapeutic strategy for BCL6-dependent lymphomas.

Chromatin regulatory proteins play a central role in orchestrating the function of germinal centers (GC), where mature B cells must transiently repress genes involved in immune signaling, cell-cycle checkpoints, and DNA damage responses to undergo rapid proliferation and somatic hypermutation and allow for successful immunoglobulin affinity maturation. The transition through this hyperproliferative and genetically unstable state must be tightly regulated, and deregulation of this process can lead to malignant B-cell transformation. Based on prior observations showing loss of histone methylation at enhancers for genes repressed in GC B cells, Hatzi and colleagues investigated the role of histone demethylases in regulating GC formation and function. Among histone demethylases, LSD1 was most consistently upregulated in GCs, and conditional deletion of Lsd1 in GC B cells significantly impaired the formation of GCs and their ability to generate high-affinity antibodies. Lsd1-deficient B cells exhibited increased enhancer chromatin accessibility and increased expression of genes normally silenced in GC B cells that are also targets of the transcriptional repressor BCL6, a key regulator of GC function that is frequently translocated and constitutively expressed in B-cell lymphoma. BCL6 physically interacted with LSD1 and recruited LSD1 to its target genes, indicating that LSD1 acts in concert with BCL6 to facilitate proliferation and dampen immune signaling during humoral immune responses. Lsd1 deletion in mice with constitutive Bcl6 expression also rescued BCL6-driven GC hyperplasia, delayed lymphomagenesis, and prolonged survival, demonstrating that LSD1 is also required for BCL6-driven GC B-cell transformation. These findings raise the possibility that LSD1 could be a therapeutic target in BCL6-dependent lymphomas; however, catalytic inhibition of LSD1 did not have the same effect on GC formation as total LSD1 loss, and an LSD1 domain required for protein–protein interactions was instead required for lymphoma cell proliferation, raising the possibility that inhibitors that destabilize LSD1 may have activity in BCL6-driven lymphomas.

Hatzi K, Geng H, Doane AS, Meydan C, LaRiviere R, Cardenas M, et al. Histone demethylase LSD1 is required for germinal center formation and BCL6-driven lymphomagenesis. Nat Immunol 2019;20:86–96.

Notes

Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/CDNews.

  • ©2019 American Association for Cancer Research.
View Abstract
PreviousNext
Back to top
Cancer Discovery: 9 (2)
February 2019
Volume 9, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
BCL6-Driven Lymphoma Is Dependent on LSD1 Corepression
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
BCL6-Driven Lymphoma Is Dependent on LSD1 Corepression
Cancer Discov February 1 2019 (9) (2) 162; DOI: 10.1158/2159-8290.CD-RW2018-216

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
BCL6-Driven Lymphoma Is Dependent on LSD1 Corepression
Cancer Discov February 1 2019 (9) (2) 162; DOI: 10.1158/2159-8290.CD-RW2018-216
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • Structures Identify Selpercatinib and Pralsetinib Resistance Mechanisms
  • Computational Tool Characterizes Previously Unidentified Tumor Subtypes
  • Deep Learning Algorithm Aids Breast Cancer Detection by Mammography
Show more Research Watch

Lymphoma

  • Metabolic Adaptation to Lymphoma Suppresses NK-Cell Antitumor Function
  • TBL1XR1 Mutations Bias toward Memory B-cell Fate to Promote Lymphoma
  • Mutant EZH2 Drives Follicular Lymphoma by Altering B-cell Dependencies
Show more Lymphoma
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement